Cwm LLC Increases Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Cwm LLC increased its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 63.0% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 750 shares of the medical equipment provider’s stock after purchasing an additional 290 shares during the quarter. Cwm LLC’s holdings in Lantheus were worth $82,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Oliver Luxxe Assets LLC acquired a new stake in shares of Lantheus during the 1st quarter worth about $547,000. Allspring Global Investments Holdings LLC raised its stake in shares of Lantheus by 25.9% during the first quarter. Allspring Global Investments Holdings LLC now owns 88,046 shares of the medical equipment provider’s stock valued at $5,480,000 after purchasing an additional 18,119 shares during the period. State of Michigan Retirement System raised its stake in shares of Lantheus by 2.4% during the first quarter. State of Michigan Retirement System now owns 16,800 shares of the medical equipment provider’s stock valued at $1,046,000 after purchasing an additional 400 shares during the period. Legacy Wealth Asset Management LLC increased its stake in shares of Lantheus by 19.9% in the first quarter. Legacy Wealth Asset Management LLC now owns 9,509 shares of the medical equipment provider’s stock worth $592,000 after buying an additional 1,581 shares during the last quarter. Finally, Commonwealth Equity Services LLC increased its stake in shares of Lantheus by 23.4% in the first quarter. Commonwealth Equity Services LLC now owns 15,214 shares of the medical equipment provider’s stock worth $947,000 after buying an additional 2,880 shares during the last quarter. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Lantheus

In related news, Director Mary Anne Heino sold 10,481 shares of the stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $95.50, for a total value of $1,000,935.50. Following the completion of the transaction, the director now owns 454,923 shares in the company, valued at $43,445,146.50. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, Director Gerard Ber sold 15,500 shares of the stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the transaction, the director now owns 21,221 shares in the company, valued at $2,047,402.08. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Mary Anne Heino sold 10,481 shares of the company’s stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $95.50, for a total transaction of $1,000,935.50. Following the completion of the sale, the director now directly owns 454,923 shares of the company’s stock, valued at $43,445,146.50. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 27,981 shares of company stock worth $2,689,156 in the last 90 days. Corporate insiders own 1.50% of the company’s stock.

Lantheus Stock Up 0.4 %

Lantheus stock opened at $110.30 on Friday. The company has a 50-day simple moving average of $107.32 and a 200-day simple moving average of $92.93. The firm has a market capitalization of $7.66 billion, a P/E ratio of 18.08 and a beta of 0.50. The company has a debt-to-equity ratio of 0.55, a quick ratio of 4.41 and a current ratio of 4.68. Lantheus Holdings, Inc. has a one year low of $50.20 and a one year high of $126.89.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 EPS for the quarter, missing the consensus estimate of $1.68 by ($0.07). The firm had revenue of $394.10 million for the quarter, compared to the consensus estimate of $382.12 million. Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The firm’s revenue was up 22.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.40 EPS. As a group, equities analysts expect that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Truist Financial decreased their price objective on shares of Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a report on Thursday, August 1st. B. Riley lifted their price objective on shares of Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Leerink Partners lifted their price objective on shares of Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a report on Thursday, July 11th. Redburn Atlantic assumed coverage on shares of Lantheus in a report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price objective for the company. Finally, JMP Securities decreased their price objective on shares of Lantheus from $130.00 to $125.00 and set a “market outperform” rating for the company in a report on Thursday, August 1st. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $126.00.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.